Mirvetuximab soravtansine-gynx approbatur ab USFDA pro FRα positivo, platino-resistenti epitheliali ovarii, tubae fallopianae, vel cancri peritonaei primarii.
Martii 2024: Cibus et Administration medicamentis approbationem concessit mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.
Orci iudiciis
MESO-CAR T Cellae Therapy pro Relapso et Refractory Epithelial Cancer
March 2023: Brief Summary: The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell therapy can be used to treat epithelial ovarian cancer that has come back or stopped responding to other..
mirvetuximab soravtansine-gyn
Mirvetuximab soravtansine-gynx, conceditur approbatione accelerata pro positivo, platino-resistenti epitheliali ovarii, tubae fallopianae, vel cancri peritonaei.
Novembris 2022: Pro aegris adultis, qui unam ad tres diaetam systemicam priorum curationis habuerunt, et receptorem folatium alpha (FR) positivum, platinum repugnans, epithelialem ovarium, tubum fallopianum, vel cancrum peritonaei primarii, in F.
SCALPELLUM, Mekinist, Tamoxifen, Trametinib
Nova curatio quae in gradu humili et serooso cancer ovarii notatur
Maii 2022: Trametinib potest fieri novum vexillum curationis recurrentis, cancri ovarii serosi serosi (Mekinist). Secundum studium inventionum editae in mense Februario 2022 exitus Lanceati, trametinib utramque chemotherapyam pulsant.
Cytalux, NCT03180307, pafolacianine, Target Laboratories
Pafolacianina approbatur ad cognoscendas laesiones cancer ovarii maligni
Ian 2022: Pafolacianina (Cytalux, In Target Laboratoriis, LLC), agens imaginatio optica, licentiatus est a Cibus et medicamentis Administrationis aegris adultis cum cancer ovarii adiuvans ad detectionem interoperativam.
Niraparib
Niraparib possit prodigiosus praecessi pro pectus cancer et clitoris;
Pectus pectus & ovarii cancerIf es, patientes estote et ovarian cancer, fit ut quem tu es cancer de BRCA1 / II post mutationem transiens per geneticae expertus est, et vita vestra est salvus erit. Global Oncolog Secundum ..
Acalabrutunib, Avelumab, Lorem CART, Dabrafanib, Kymriah, tardus medicaménta utíliter, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Tardus medicinae in curatio cancer est
July 2021: Check out the latest drugs in the treatment of cancer. Every year, after examining the trials and other important factors, the USFDA approves drugs, and thus cancer patients can now believe that a cure is very near. ..